Use this url to cite publication: https://hdl.handle.net/20.500.12512/111882
Options
Benefits of early salvage therapy on oncological outcomes in high-risk prostate cancer with persistent PSA after radical prostatectomy / D. Milonas, A. Laenen, Z. Venclovas, L. Jarusevicius, G. Devos, S. Joniau
Type of publication
Straipsnis Web of Science duomenų bazėje / Article in Web of Science database (S1a)
Author(s)
Leuven University Hospital, Leuven, Belgium | ||
Laenen, Annouschka L. | KU Leuven, Leuven Biostatistics and Statistical Bioinformatics Center, Leuven, Belgium | |
Devos, Gaëtan | Leuven University Hospitals, Leuven, Belgium | |
Joniau, Steven | Leuven University Hospitals, Leuven, Belgium |
Title
Benefits of early salvage therapy on oncological outcomes in high-risk prostate cancer with persistent PSA after radical prostatectomy / D. Milonas, A. Laenen, Z. Venclovas, L. Jarusevicius, G. Devos, S. Joniau
Publisher (trusted)
Springer International Publishing |
Is Referenced by
Date Issued
Date Issued |
---|
2022-02-01 |
Extent
p. 371-378.
Is part of
Clinical and Translational Oncology. Cham : Springer International Publishing, 2022, vol. 24, no. 2.
Version
Originalus / Original
Description
Open Access (OA)
Field of Science
Abstract
Background Patients with prostate-specific antigen (PSA) persistence are at the increased risk of disease progression. The aim of our study was to evaluate the impact of early salvage therapy on oncological outcomes in patients with persistent PSA after radical prostatectomy (RP). Methods Within a single tertiary centre database, we identified men with persistent (≥ 0.1 ng/ml) versus undetectable (< 0.1 ng/ml) PSA 4–8 weeks after RP for high-risk prostate cancer (HRPCa). The cumulative incidence function was used to estimate cancer-specific survival (CSS) and clinical progression-free survival (CPFS). The Kaplan–Meier method was used to estimate overall survival (OS). The effects on oncological outcomes of salvage radiotherapy (SRT) ± androgen deprivation therapy (ADT) vs. ADT monotherapy were tested in the subgroup of patients with persistent PSA. Results Of 414 consecutive patients who underwent RP for HRPC, 125 (30.2%) had persistent PSA. Estimated 10-year CPFS, CSS and OS for men with persistent vs. undetectable PSA were 63.8% vs. 93.5%, 78.5% vs. 98.3% and 54% vs. 83.2% (all p < 0.0001), respectively. In men with persistent PSA, ADT alone was associated with higher risk (hazard ratio (HR) for worse CSS (HR 3.9, p = 0.005) and OS (HR 4.7, p < 0.0001) but not for CP (HR 1.6, p = 0.2) when compared with SRT ± ADT. Conclusion In patients who underwent RP for HRPCa, persistent PSA was associated with poor oncological outcomes. Early SRT ± ADT resulted in significantly improved CSS and OS in men with persistent PSA comparing with early androgen deprivation monotherapy.
Type of document
type::text::journal::journal article
ISSN (of the container)
1699-048X
1699-3055
WOS
000690697400002
Other Identifier(s)
(LSMU ALMA)990001044650107106
Coverage Spatial
Šveicarija / Switzerland (CH)
Language
Anglų / English (en)
Bibliographic Details
25
Funding(s)
Funding(s) |
---|
FWO |
Journal | IF | AIF | AIF (min) | AIF (max) | Cat | AV | Year | Quartile |
---|---|---|---|---|---|---|---|---|
Clinical & Translational Oncology | 3.4 | 5.7 | 5.7 | 5.7 | 1 | 0.596 | 2022 | Q3 |
Journal | IF | AIF | AIF (min) | AIF (max) | Cat | AV | Year | Quartile |
---|---|---|---|---|---|---|---|---|
Clinical & Translational Oncology | 3.4 | 5.7 | 5.7 | 5.7 | 1 | 0.596 | 2022 | Q3 |
Journal | Cite Score | SNIP | SJR | Year | Quartile |
---|---|---|---|---|---|
Clinical and Translational Oncology | 6.2 | 0.887 | 0.831 | 2022 | Q2 |